COVID-19 Clinical Trial
Official title:
Repurposing of Chlorpromazine in Covid-19 Treatment
This study evaluates the effects of the addition of chlorpromazine to the standard therapeutic protocol in COVID-19 patients hospitalized for respiratory symptom management (score 3-5 WHO Ordinal Scale for Clinical Improvement).
This study evaluates the effects of the addition of chlorpromazine to the standard
therapeutic protocol in COVID 19 patients hospitalized for respiratory symptom management
(score 3-5 WHO Ordinal Scale for Clinical Improvement).
The investigators have observed in GHU-Paris psychiatry Hospital units (140 beds),
significantly lower prevalence of symptomatic and severe forms of COVID-19 in patients (3%)
than in the health workers operating in the same facilities (19% of nurses and 18% of
physicians). COVID-psychiatry units report similar feedback in France, Spain, and Italy. One
hypothesis could be that psychotropic drugs have a protective action on COVID-19 and protect
patients from symptomatic and virulent forms of COVID-19.
This hypothesis is consistent with research studies that have shown that several psychotropic
drugs inhibit in vitro viral replication of the coronaviruses MERS-CoV and SARS-CoV-1. The
SARS-CoV-2 has many characteristics in common with the coronavirus family and has
phylogenetic similarities to the SARS-CoV-1 engaged in the 2002-2003 outbreak. It is,
therefore, possible that one or more psychotropic drugs having demonstrated efficacy against
MERS-CoV and SARS-CoV-1 also have anti-SARS-CoV-2 antiviral activity.
The current global epidemic of COVID-19, with a high number of deaths in many countries,
makes it urgent to search drugs potentially useful to reduce the severity and lethality of
the infection. Drug repositioning represents a possible alternative to the news medicines
discovery. This strategy makes it possible to eliminate many stages of development; it makes
it possible to deploy a therapy whose side effects are known and which physicians already
well know how to handle.
To confirm the hypothesis of the antiviral action of chlorpromazine on SARS-CoV-2, a
preclinical in vitro experiment began in April 2020 at the level III high-security biological
laboratory at the Pasteur Institute (in collaboration with the GHU PARIS Psychiatry &
Neurosciences). The first results are encouraging and show a marked antiviral effect of
chlorpromazine on SARS-CoV-2. Technical replicas are underway to validate these preliminary
results.
By integrating all these evidence, the investigators hypothesize that chlorpromazine could
decrease the unfavorable evolution of COVID-19 infection when administered at the onset of
respiratory signs.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|